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Controversies Regarding the Utility of 
Lymphadenectomy in Endometrial Cancer 




The value of lymphadenectomy (LND) in the management of endometrial cancer remains 
controversial. Although it is required for the surgical staging of the disease (FIGO 2009) and 
its prognostic value is indisputable, its therapeutic benefit remains a matter of debate. 
Furthermore, systematic pelvic (PLND) and para-aortic lymphadenectomy (PaLND) cause 
morbidity, even when performed using minimally invasive surgical techniques. A reliable 
means of sentinel lymph node (SLN) mapping may be the way forward. In this chapter we 
review the literature surrounding this topic, identify areas for research and suggest a 
pragmatic approach to managing this dilemma.  
2. Overview 
The lifetime risk of a woman in the United States to develop uterine cancer is 2.5%. It is the 
fourth most common cancer in women and accounts for 6% of all female cancers and 3% of 
cancer-related deaths (Jemal et al., 2010). Two different clinico-pathological subtypes of 
endometrial cancer are recognized: Type I, which is endometrioid and estrogen-related, and 
Type II, which is non-endometrioid and non-estrogen-related.  
When the disease is confined to the uterus, a hysterectomy and bilateral salpingo-
oophorectomy would constitute adequate treatment. If the disease has spread outside the 
uterus, adjuvant treatment is required to maximize the potential for cure. At the time of 
diagnosis approximately 85% of endometrioid cancers are confined to the uterine corpus 
and are therefore associated with a favorable five-year survival rate of 83% (Creasman et al., 
2006). In the Western world at least 85% of newly diagnosed endometrial cancers are 
endometrioid in type (Amant et al., 2005; Creasman et al., 2006). As the propensity for 
lymph node metastasis in these patients can vary from clinically negligible to 20%, 
depending on the grade and stage of presentation, management of this subtype is fraught 
with ambiguity.  In non-endometrioid cancers, 35% have already spread beyond the uterine 
corpus at presentation. Among the non-endometrioid uterine cancers, clear cell and 
papillary serous cancers are the worst offenders, with extra-uterine metastasis occurring in 
33% and 41% of cases, respectively, which is reflected in correspondingly low five-year 
survival rates of 63% and 53%, respectively (Creasman et al., 2006).  
Following primary surgical treatment, adjuvant treatment is tailored according to the risk of 
lymph node metastasis and recurrent disease. The current method of risk stratification uses 
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patient-related factors as well as the definitive pathological findings identified to be 
associated with increased risk of lymph node metastasis and recurrence to group patients 
into low-, intermediate- and high-risk categories.  Other determinate factors are age, tumor 
grade, non-endometrioid subtype and extension of the disease, including depth of 
myometrial invasion and lymphovascular space invasion (LVSI) (Creasman et al., 1987; 
Kadar et al., 1992; Keys et al., 2004; Morrow et al., 1991). 
 






5 years (%) 
Low Ia, Grade I & II <3 <5 
Intermediate 
Risk factors (RF): 




Low others 3-5 10-15 
High 
≥70 years + 1 RF 
≥50 years + 2 RF 
any age with 3 RF 
10-30 20-25 
High 
Stage II-IV, non-endometrioid 
uterine cancers 
>30 >25 
Table 1. Classification of endometrial cancers adjusted to FIGO 2009. 
The disadvantage of this system is that lymph node metastasis is presumed rather than 
known for certain, and a proportion of patients will be over-treated with adjuvant 
treatment. Furthermore, if removal of the affected nodes has a therapeutic value, and 
evidence suggests it has (please refer to section 6), patients would miss out on the survival 
advantage conferred by a systematic lymphadenectomy.  Having access to information 
about lymph node status pre-operatively would allow surgery to be tailored accordingly. 
Below, we discuss the currently available methods for pre-operative assessment of the 
spread of disease. 
3. Pre-operative assessment of the spread of disease 
3.1 CA 125 
Four studies have evaluated the role of CA 125 in evaluation of patients with endometrial 
cancer. All four conclude that a high CA 125 cut-off, ranging from 20 to 40U/ml., is an 
independent risk factor for extra-uterine disease or lymph node metastasis. Nevertheless, its 
sensitivity and specificity are only around 80% (Chung et al., 2006; Han et al., 2010; Hsieh et 




Most patients with endometrial cancer will have a transvaginal ultrasound (TVS) as it is the 
imaging procedure of choice to assess post-menopausal bleeding, the most common 
presenting symptom. TVS is a non-invasive, readily available and inexpensive test that has a 
very high sensitivity of 96% for raising suspicion about the presence of endometrial cancer 
www.intechopen.com
 
Controversies Regarding the Utility of Lymphadenectomy in Endometrial Cancer 
 
103 
when using a cut-off of ≥5mm endometrial thickness. Its specificity varies between 61% and 
81% for all endometrial diseases (Fleischer, 1997; Smith-Bindman et al., 1998). False-negative 
rates have been reported at around 1% and are due to adenomyosis or distortion of the 
endometrial lining by fibroids (Smith-Bindman et al., 1998). If morphologic features such as 
endometrial heterogeneity were added to endometrial thickness, then specificity and the 
false-negative rate might be improved (Dubinsky, 2004). 
After the diagnosis of endometrial cancer is made, TVS could provide information about the 
depth of myometrial invasion. Loubeyre et al. (2011) reviewed the correlation between the 
depth of myometrial invasion on TVS and the final pathology in eight studies with a total of 
605 patients with endometrial cancer. They found the sensitivity to be 80% (range 58% to 
95%) and so too the specificity (range 71% to 92%). Evaluation of cervical involvement by 
TVS is less informative, with sensitivities varying between 54% and 88% and specificity 
between 87% and 100% (Celik et al., 2010; Lee et al., 2011; Loubeyre et al., 2011). 
The weaknesses of TVS are that it is operator-dependent and lymph nodes cannot be 
properly evaluated.  
3.2.2 CT 
CT scan is considered inferior to TVS in determining the depth of myometrial invasion 
(accuracy around 60%). The ability of CT scan to identify cervical involvement has not been 
properly investigated. The value of multidetector CT in the staging of endometrial cancer 
has yet to be explored (Lee et al., 2011; Loubeyre et al., 2011). Using a 1cm cut-off to evaluate 
pelvic and para-aortic lymph nodes, the sensitivity of CT is only 50% (range 44% to 66%)—
no better than flipping a coin; its specificity is 95% (range 73% to 98%) (Lee et al., 2011). This 
poor correlation is due to the fact that only 39% of metastatic lymph nodes are enlarged and 
37% are smaller than 2mm (Creasman et al., 1987; Mariani et al., 2000). For the same reason, 
MRI and PET-CT have similar results in detecting metastatic lymph nodes.   
3.2.3 MRI 
The imaging procedure of choice to assess patients with endometrial cancer is MRI, but it is 
an expensive test and, as mentioned before, is ineffective in detecting metastatic lymph 
nodes. However, MRI is superior to TVS and CT in evaluating the depth of myometrial 
invasion as well as cervical involvement (Loubreyre et al., 2011; Lee et al., 2011, on behalf of 
the American College of Radiology). Loubeyre et al. (2011) reviewed the correlation between 
depth of myometrial invasion on MRI and final pathology in nine studies with a total of 
1,115 patients with endometrial cancer. Sensitivity ranged from 56% to 88% and specificity 
from 74% to 100%. This group also reviewed the correlation between cervical involvement 
on MRI and final pathology in five studies with a total of 623 patients with endometrial 
cancer. Sensitivity ranged from 47% to 72% and specificity from 83% to 100%. In its pre-
treatment evaluation of endometrial cancer, the American College of Radiology indicates 
that the accuracy of MRI in predicting myometrial involvement ranges from 85% to 92%, 
cervical involvement from 86% to 95% and overall staging from 85% to 93% (Lee et al., 
2011). 
3.2.4 PET 
The role of PET in endometrial cancer is more in the detection of disease recurrence than in 
the pre-operative evaluation of extra-uterine disease (Lee et al., 2011).  
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4. Pre-operative assessment of grade and histological subtype of the disease 
4.1 Pathology 
In addition to a TVS, a patient with post-menopausal bleeding needs a tissue diagnosis. This 
can be done by pipelle biopsy (office endometrial biopsy) or dilatation and curettage (D&C). 
The sensitivity of pipelle biopsy in detecting endometrial cancer is 99.6%. The sensitivity of 
D&C is similar; it serves as the diagnostic procedure when pipelle biopsy is not feasible or is 
inadequate (Dijkhuizen et al., 2000). After the diagnosis of endometrial cancer is made, pre-
operative assessment of the aggressiveness of the disease is very important to tailor the 
surgery. Patients with a high-grade endometrial cancer have a 15% to 20% risk of having 
metastatic lymph nodes (Creasman et al., 1987). Therefore, the ability to grade the tumor 
accurately on the diagnostic sample, be it a pipelle biopsy or a D&C, is crucial.  
A D&C reflects the final FIGO grade more accurately than a pipelle biopsy. Leitao et al., 
(2009) reported a higher grade at the time of hysterectomy in 8.7% of patients when the 
diagnosis was made with a D&C, compared to 17.4% with a pipelle biopsy. Obermaier et al. 
(1999) found that 20% of Grade 1 endometrial cancers on D&C were upgraded to Grade 2 
(or Grade 3 in 2% to 3% of cases) while 4% were downgraded at final pathology. In 
summary, pre-operative FIGO Grade 1 endometrioid endometrial cancer correlates in 80% 
to 85% of cases with the grade on the final hysterectomy specimen. The difference between 
pipelle biopsy and D&C does not warrant extra anesthesia. Changing from the three-grade 
FIGO system to a binary system does not improve accuracy sufficiently to warrant replacing 
the FIGO system, which is currently in use worldwide. However, molecular tests may have 
greater potential to support the binary system in the future (Clarke & Gilks, 2010). In a 
review of Stage III cases treated at our institution, we found that less than half were 
suspected preoperatively (Denschlag et al., 2007). A recent French multicentre study on 
sentinel lymph node mapping, found that 29% of tumors thought to be grade 1 
preoperatively or intraoperatively, were upgraded to grade 2 or 3 or at final histology and 
7% of patients thought to have type I tumors had type 2 endometrial cancer at definitive 
histology (Ballester et all 2010). 
4.2 Conclusion 
Identifying metastatic lymph nodes by currently available imaging techniques is only as 
sensitive as flipping a coin (50%). Assessing risk factors for metastatic lymph nodes, such as 
depth of myometrial invasion and cervical involvement, is most accurate with MRI, 
reaching at least 85% (in study circumstances) for both risk factors. Pre-operative assessment 
of Grade 1 tumors correlates with the final grade in 80% to 85% of cases.  
This means that approximately one patient in five is underestimated pre-operatively for risk 
factors that include depth of myometrial invasion and/or cervical involvement and/or 
tumor grade. Consequently, tailoring surgery based on pre-operative assessment alone is 
not adequate. 
5. Intra-operative assessment 
5.1 Palpation of lymph nodes 
Intra-operative palpation of pelvic or para-aortic lymph nodes will reveal only 39% of the 
metastatic lymph nodes (Mariani et al., 2000). Creasman et al. (1987) have already shown 
that 37% of metastatic lymph nodes are smaller than 2mm. So neither pre-operative imaging 
nor intra-operative palpation is accurate enough to dispense with surgical excision. 
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5.2 Gross inspection 
Assessment of the depth of myometrial invasion of an endometrial cancer by gross visual 
examination has been studied in three prospective studies (ranging from 148 to 403 
patients). Compared to definite hystopathological findings, sensitivity varies from 71% to 
79% and specificity from 93% to 96%. Evaluation of cervical involvement by gross inspection 
has never been studied (Loubreyre et al., 2011).  
5.3 Frozen section  
Given our inability to predict lymph node metastasis pre-operatively with accuracy, can 
intra-operative frozen section analysis help determine which patients should have a 
systematic PLND and PaLND?  The literature on this is conflicting. 
Correlations of 58% to 96% for grade with intra-operative frozen section analysis and final 
pathologic results have been reported. A similar variation is reported in the accuracy of 
intra-operative section analysis of depth of myometrial invasion (72% to 95%) as well as of 
cervical involvement (66% to 97%) (Frumovitz et al., 2004; Loubeyre et al., 2011). 
Several retrospective studies, which used a combination of risk factors (grade and depth of 
myometrial invasion, histological subtype) to compare intra-operative frozen section 
analysis and final pathologic results, found that the correlation was not sufficient to 
dispense with surgical staging  (Frumovitz et al., 2004; Denschlag et al., 2007; Papadia et al., 
2009). According to Papadia et al., 78% of patients undergo appropriate surgery, while 16% 
are under-staged and 6% over-staged.  
5.4 Adding tumor size 
In an attempt to increase the accuracy of frozen section analysis, several investigators have 
studied the benefit of factoring in tumor size as determined intraoperatively. In 1987 Schink 
et al. described that patients with clinical Stage 1 endometrial cancer had only a 4% risk of 
lymph node metastasis if their endometrial cancer was ≤2cm. The Mayo Clinic in Rochester, 
Minnesota, uses a thorough intra-operative frozen section to identify a sub-group of patients 
with endometrioid adenocarcinoma in whom the risk of lymph node metastasis is negligible 
and who therefore do not warrant lymphadenectomy. The characteristics are:  Type I, 
Grades 1 and 2; myometrial invasion less than 50%; primary tumor diameter less than 2cm, 
(Mariani et al. 2008).  
The concept of adding tumor size to improve the ability of frozen section to correctly 
identify low-risk patients was evaluated by Yanazume et al. (2011) in a retrospective study 
of 228 patients.  They used tumor size of ≤3cm as their cut off. This study found that a Grade  
1 or 2 endometrial cancer, with a tumor diameter of ≤3cm and ≤50% myometrial invasion, 
accurately predicts the absence of lymph node metastasis.  
5.5 Conclusion 
The palpation of lymph nodes during a laparotomy should not be used to determine the 
need for a systematic PLND and PaLND. Frozen section analysis is useful to distinguish a 
benign from a malignant lesion, but it has limitations with regard to time involvement, 
inadequate sampling (only part of the tumor) and the technique of rapid freezing itself. 
However, despite these constraints, a detailed and thorough intra-operative frozen section 
that assesses subtype, grade, myometrial invasion and tumor size is preferable to the 
alternatives, namely, that of an unnecessary lymphadenectomy with its attendant 
complications in low risk patients, or not carrying out a systematic lymphadenectomy in 
patients at high risk of lymph node metastasis.  
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6. Surgical staging 
As discussed in the previous section, it is clear that surgical staging and knowledge of lymph 
node status plays a very important role in the management of patients with endometrial 
cancer. What is not clear is what constitutes an adequate LND. The practice varies from 
selective sampling of accessible nodes to systematic LND. Is the latter necessary? Is a PLND 
adequate or is a PaLND required in addition to a PLND?  If a PaLND is required, what are the 
limits of dissection? What are the additional risks of a LND? When are these additional risks 
justified? Does LND have a therapeutic effect? Below, we discuss the studies that have tried to 
address these questions.  
6.1 Definitions  
For a systematic PLND, all lymph nodes and fatty tissue between the external and internal 
iliac arteries, from the bifurcation of the common iliac artery up to the circumflex vein and 
above the obturator nerve, should be removed. A systematic PaLND includes resection of all 
lymph nodes and fatty tissue overlying the common iliac artery, vena cava and aorta 
anteriorly up to the renal vessels and extending laterally to the edge of the psoas major 
muscle.  
6.2 The randomized controlled trials on lymphadenectomy  
To date, two randomized controlled trials (Benedetti Panici et al. in 2008 and the MRC 
ASTEC trial 2009) have investigated whether the addition of PLND to standard 
hysterectomy with bilateral salpingo-oophorectomy improved overall survival and disease-
free survival in patients with preoperative Stage I endometrial cancer.  
6.2.1 Benedetti Panici et al., 2008 
In this Italian RCT, the role of systemic PLND or no PLND in early-stage endometrioid or 
adenosquamous endometrial cancer (FIGO 1988) was examined. Patients with Stages IA and 
IB Grade I, were excluded; 514 patients were randomized to undergo PLND (n=264) or not 
(n=250). A minimum of 22 PLNs were removed; median was 30. PaLND and adjuvant 
radiotherapy were left to the discretion of the treating physician; 26% in the PLND group 
had PaLND compared to 2% in the no-PLND group; the median number of PaLN’s 
removed in the LND group was four. The proportion of patients who received adjuvant 
radiotherapy was similar in both groups: ±31-35%. At a median follow-up time of 49 
months, no difference in the disease-free or overall survival rates was seen between the two 
groups. The estimated blood loss and the number of intra-operative complications were 
similar in both arms, but operating time and hospital stay were longer in the PLND group. 
Furthermore, more post-operative complications were noted in the PLND group, 
predominantly due to the formation of lymphocysts and lymphedema (35 versus 4). The 
PLND group was diagnosed with 13% metastatic LN versus only 3% in the no-PLND group. 
The authors concluded that although disease-free or overall survival is not improved, a 
systemic PLND significantly improved surgical staging.  
6.2.2 ASTEC Trial, 2009 
Eighty-five centers in four countries participated in the ASTEC Trial, randomizing 1,408 
women with histologically proven endometrial cancer that was pre-operatively (clinically) 
thought to be confined to the uterus (despite PLN enlargement on CT or MRI), to standard 
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surgery with or without systemic PLND. At a median follow-up time of 37 months there 
was no difference in disease-free or overall survival in both groups. According to the 
authors, PLND cannot be recommended as a routine procedure for therapeutic purposes 
outside of clinical trials. 
However, the ASTEC Trial had several serious shortcomings: 
 20% of patients in the systemic PLND group had ≤4 nodes removed; only 40% of the 
patients in the systemic PLND group had >14 PLN harvested.  
 Furthermore, about half the cases were well-differentiated Stage IA or IB, where the risk 
of nodal metastasis is 3% to 5%.  
 In a large prospective RCT, risk factors tend to be equalized in the two arms. 
Nevertheless, the PLND group had 3% more poor histotypes, 3% more Grade 3 lesions, 
3% more LVSI and 10% more deep myometrial invasion. Although these are minor 
variances, in large groups this could influence small differences. 
 Patients were randomized to receive adjuvant therapy regardless of node status.  
6.3 Observational studies on the effect of lymphadenectomy on survival 
6.3.1 Cragun et al., 2005 
In a retrospective analysis of 509 patients, Cragun et al. (2005) noted that patients with 
poorly differentiated cancers having more than 11 pelvic nodes removed had improved 
overall survival (hazard ratio [HR] 0.25; P < .0001) and progression-free survival (HR 0.26; P 
< .0001) compared with patients having poorly differentiated cancers with 11 or fewer nodes 
removed. Among patients with cancers of Grades 1 to 2, the number of nodes removed was 
not predictive of survival. In multivariate analysis, a more extensive node resection 
remained a significant prognostic factor for improved survival in intermediate-/high-risk 
patients after adjusting for other factors including age, year of diagnosis, stage, grade, 
adjuvant radiotherapy and the presence of positive nodes (P < .001). Performance of selective 
PaLND was not associated with survival. 
6.3.2 Chan et al., 2006 
Further evidence for the prognostic and therapeutic benefits for a thorough LND came from 
Chan et al., who used the United States National Cancer Institute’s  Surveillance, 
Epidemiology and End Results Program dataset of 39,396 women with endometrioid uterine 
cancer. They compared 12,333 patients who underwent surgical-staging procedures, 
including LND, with 27,063 patients who did not receive a LND to determine the potential 
therapeutic role of LND in women with endometrioid corpus cancer. They found that the 
five-year disease-specific survival was significantly improved by lymphadenectomy, and 
that with increasingly high-risk disease, the survival advantage conferred by LND was 
progressively greater. The five-year disease-specific survival for Stages I, II, III and IV 
patients who underwent LND was 95.5%, 90.4%, 73.8% and 53.3%, respectively, compared 
with 96.6%, 82.2%, 63.1% and 26.9% for those who did not (P > 0.05 for Stage I, P < 0.001 for 
Stages II to IV). In the subset of patients with Stage I, Grade 3 disease, those who underwent 
LND, had a better disease-specific survival than those who did not (90% versus 85%; P 1⁄4 
0.0001). However, no benefit for LND was identified for patients with Stage I, Grade 1 (P 1⁄4 
0.26) and Grade 2 (P 1⁄4 0.14) disease. 
The group also used the data from the 12,333 patients who underwent LND to determine 
whether the node count or extent of the LND had a therapeutic benefit, and they found that 
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it did in women with intermediate-/high-risk endometrioid cancer but not those with low-
risk endometrial cancer. In the intermediate-/high-risk patients (Stage IB, Grade 3; Stages IC 
and II to IV, all grades), a more extensive lymph node resection (1, 2-5, 6-10, 11-20, and >20) 
was associated with improved five-year disease-specific survivals across all five groups at 
75.3%, 81.5%, 84.1%, 85.3% and 86.8%, respectively (P < .001). For Stage IIIC to IV patients 
with nodal disease, the extent of node resection significantly improved survival from 51.0%, 
53.0%, 53.0% and 60.0%, to 72.0%, (P <.001). However, no significant benefit of lymph node 
resection in low-risk patients could be demonstrated (Stage IA, all grades; Stage IB, Grade 1 
and 2 disease; P ¼ 0.23). In multivariate analysis, a more extensive node resection remained 
a significant prognostic factor for improved survival in intermediate-/high-risk patients 
after adjusting for other factors, including age, year of diagnosis, stage, grade, adjuvant 
radiotherapy and the presence of positive nodes (P <.001). In a follow-through study on 
11,443 patients, Chan et al. (2007) investigated the association between the number of lymph 
nodes examined and the probability of detecting at least a single lymph node involved by 
metastatic disease in patients with endometrioid corpus cancer to define what constitutes an 
adequate LND. Their results suggest that the ideal node count is 21 to 25 lymph nodes. 
Although these are retrospective analyses, the strength of the data lies in the size of the 
sample and the fact that the study population reflects real-life practices across a range of 
units from community hospitals to tertiary-care academic centers. The limitations include 
the lack of detail regarding the location and size of the lymph nodes resected, specifically on 
what the contribution of PaLND is to the sample.  
6.3.3 Para-aortic lymphadenectomy 
There is evidence that patients with high-intermediate and high-risk endometrial cancer 
have 10% to 25% risk of metastatic PaLN (Kadar et al., 1992; Keys et al., 2004; Morrow et 
al., 1991). About 50% of patients with metastatic PLN have metastasis in the PaLN 
(Mariani et al., 2008; Watari et al., 2005). Sixteen percent of patients with high-risk 
endometrial cancer have metastasis only to the PaLN and not to the PLN (Mariani et al., 
2008) and 77% of patients with para-aortic metastases harbor disease above the inferior 
mesenteric artery. It would appear that PaLND, when indicated, should be systematic and 
extend to the renal vessels. Although Abu-Rustum et al. (2009) reported that in their 
patients only 1% had isolated para-arotic metastasis (with negative pelvic nodes), they 
used a count of eight pelvic nodes as indicating a satisfactory pelvic lymphadenectomy 
and the retrieval of one para-arotic lymph node below the inferior mesenteric artery as 
evidence of a PaLND. Most gynecologic oncologists consider these LN counts inadequate 
to make firm conclusions. 
6.3.4 SEPAL study 2010 
Given the discordance between the findings of the large observational studies (Cragun 2005, 
Chan 2006, 2007a, 2007b) indicating a significant advantage in survival conferred by  an 
extensive lymphadenectomy, and the RCTs indicating otherwise, Yukiharu Todo and 
colleagues investigated whether it was the addition of PaLND that improved survival in 
endometrial cancer (SEPAL). They studied cohorts from two tertiary-care gynecologic 
oncology units in the city of Sapporo, Japan. Although their study is retrospective, bias was 
kept to a minimum as the centers differed in the use of PaLND, which was practiced as a 
routine standard of care in one center and not in the other. The cohorts from both centers 
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had systematic PLND; median pelvic lymph node count 34 (21 to 42) in the PLND group 
(325 patients) versus 59 (46 to 73) in the PLND and PaLND group (n=346). The number of 
PaLN counts in the two groups were 0 versus 23 (16 to 30). Patients at intermediate or high 
risk of recurrence were offered adjuvant radiotherapy or chemotherapy. Overall survival 
was significantly longer in the PLND and PaLND group than in the PLND group (HR 0.53, 
95% CI 0.38 to 0.76; p=0.0005). This association was noted in 407 patients at intermediate or 
high risk (p=0.0009), but not in low-risk patients. Multivariate analysis of prognostic factors 
showed that in patients with intermediate or high risk of recurrence, PLND and PaLND 
reduced the risk of death compared with PLND (0.44, 0.30 to 0.64; p<0.0001). Analysis of 328 
patients with intermediate or high risk who were treated with adjuvant radiotherapy or 
chemotherapy showed that patient survival improved with PLND and PaLND (0.48, 0.29 to 
0.83; p=0.0049) and with adjuvant chemotherapy (0.59, 0.37 to 1.00; p=0.0465) independently 
of one another. The authors concluded that combined PLND and PaLND is recommended 
as treatment for patients with endometrial carcinoma of intermediate or high risk of 
recurrence.  
6.4 Caveat with lymph node counts 
Although there is much debate on constitutes the optimum pathological sampling of pelvic 
lymph nodes in endometrial cancer, the importance of counting the number of lymph nodes 
detectable in the pathologic specimens is incontrovertible (Berney et al., 2010). Weingärtner 
et al. (1996) reported on the average number of PLNs found at the time of autopsy. In 30 
human cadavers (19 males and 11 females, mean age of death 64 years), it was found that 
there were 22.7±10.2 lymph nodes (ranging from 8 to 56) in the pelvis. It has been clearly 
established that lymph nodes undergo fatty involution that increases with age (>72 years), 
BMI (>27.8), diabetes, hypothyroidism and previous chemotherapy. A recent study 
confirmed this phenomenon for superficial lymph nodes in the cervical, axillary and 
inguinal regions. The fatty degeneration of lymph nodes makes their identification 
unreliable with either imaging or palpation at the time of surgery or during gross pathologic 
examination (Arango et al., 2000; Giovagnorio et al., 2005). Consequently, the value of 
lymph node counts in the elderly and in obese women with endometrial cancer is highly 
dependent on the thoroughness of the pathology technician. 
6.5 Conclusion 
In summary, it is clear that patients who have low-grade endometrioid adenocarcinoma 
with minimal myometrial invasion have very low risk of lymph node metastasis and do not 
benefit from a LND. Patients at risk of lymph node metastasis require a systematic PLND as 
well as PaLND. The latter should extend up to the renal vessels. 
7. Morbidity of lymphadenectomy and benefits of minimally invasive 
approach 
One of the factors that precludes LND in patients with endometrial cancer is the morbidity 
associated with an LND. Given that the risk factors for endometrial cancer are old age, 
diabetes, hypertension and obesity, it follows that a substantial number of women 
diagnosed with endometrial cancer have these co-morbidities, thus making them high risk 
for prolonged and technically complicated surgery. Several studies have tried to assess the 
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additional risks posed by a systematic LND and the benefits of performing the surgery by 
laparoscopy or robotic surgery.  
In a large retrospective study, Cragun et al. (2005) summarized the morbidities of LND by 
laparotomy. Two to three percent of patients had small bowel obstruction or ileus, deep vein 
thrombosis and lymphocysts requiring drainage. Patients undergoing PLND and PaLND 
required longer anesthesia time and hospital stay and had greater blood loss compared to 
those who had PLND alone. Up to 8% of patients had a wound infection. Chronic 
lymphedema of the lower limbs was observed in 2.5% (Abu-Rustum et al., 2006).  
Querleu et al. (2006) audited 1,000 patients who had a laparoscopic LND. Only 1.3% were 
converted to laparotomy. Intra- and early post-operative complication and lymphocyst 
formation rates were 2.0%(bowel complication 0.7%; urinary tract complications 0.5%; nerve 
injuries 0.5%), 2.9%  and 7.1%, respectively. 
7.1 RCTs comparing laparotomy to minimally invasive surgery for endometrial cancer 
In the LAP-2 study, an RCT carried out by the Gynecologic Oncology Group (GOG), 2,616 
patients with endometrial carcinoma confined to the uterus were randomly assigned to 
laparoscopy or laparotomy (Walker, 2009). All patients had complete surgical staging 
including PLND and PaLND. Laparoscopic-assisted vaginal hysterectomy, total 
laparoscopic hysterectomy or robotic-assisted total laparoscopic hysterectomy was 
allowed. They found that laparoscopy resulted in similar intra-operative complications, 
fewer post-operative moderate or severe adverse events (14% versus 21% by laparotomy, 
p<0.0001), shorter hospital stay, less use of pain medication and quicker resumption of 
daily activities but required longer operating time. Twenty five percent of patients 
randomized to laparoscopy were converted to laparotomy. Patients at higher risk for a 
conversion to laparotomy were elderly (>63 years) and those with metastatic disease and 
a high BMI (17% in patients with a BMI of 25kg/m2, 26% with a BMI of 35kg/m2, 57% 
with a BMI >40kg/m2).  
In an Australian RCT (n=361), which also compared total laparoscopic hysterectomy with 
abdominal hysterectomy in early endometrial carcinoma, 52% of the patients had a pelvic or 
para-aortic lymphadenectomy. Only 2.4% of patients assigned to laparoscopy were 
converted to laparotomy. Patients who had laparoscopic surgery reported significantly 
greater improvement in QoL from baseline compared with those who had laparotomy, this 
difference persisted for up to 6 months after surgery. Operating time was significantly 
longer in the laparoscopy group (138 minutes [SD 43]) versus 109 minutes [SD 34]; p=0.001). 
Intra-operative adverse events were similar between groups (laparotomy 5.6% versus 
laparoscopy 7.4%]; p=0.53), but postoperatively, twice as many patients in the laparotomy 
group experienced adverse events of Grade 3 or higher (23.2% versus 11.6%; p=0.004). The 
authors concluded that QoL improvements from baseline during early and later phases of 
recovery, and the adverse event profile, favor laparoscopy over laparotomy for the 
treatment of Stage I endometrial cancer. 
Other studies that investigated the feasibility of minimally invasive surgery (laparoscopy 
and robot-assisted surgery) in elderly and obese patients concluded that neither age nor 
BMI is a contraindication to minimally invasive procedures, as it is these patients who 
benefit the most (Boggess et al., 2008; Gehrig et al., 2008; Janda et al., 2010; Obermair et al., 
2005; Scribner et al., 2001). 
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8. Radiotherapy (RT) 
Can adjuvant radiotherapy increase disease-free and/or overall survival after standard 
surgery? In other words, can radiotherapy make up for incomplete staging if the 
characteristics of the cancer at final pathology appear to be worse? Several studies have 
addressed this question. 
8.1 Studies 
The Postoperative Radiation Therapy in Endometrial Cancer (PORTEC) Trial randomized 
715 patients with Stage IB (Grades 2 and 3) and with IC (Grades 1 and 2) endometrial cancer 
after standard surgery without PLND to observation or pelvic RT with 46 Gy. Although the 
five-year actuarial locoregional recurrence rates were 4% in the radiotherapy group and 14% 
in the control group (p=0.001, the overall survival rates were similar in the two groups: 81% 
(radiotherapy) and 85% (controls), p=0.31. Endometrial-cancer-related death rates were 9% 
in the radiotherapy group and 6% in the control group (p=0.37). Treatment-related 
complications occurred in 25% of radiotherapy patients and in 6% of the controls (p=0.0001). 
One third of the complications were Grade 2 or higher. Seven out of eight Grade 3 to 4 
complications were in the radiotherapy group (2%). The observation that the higher 
incidence of locoregional recurrences in the control group is not reflected in the overall 
survival was explained by the post-relapse survival. Twenty-three out of 51 patients with a 
locoregional relapse died, of whom only seven died due to their locoregional recurrence. By 
contrast, 21 of 30 patients with distant metastases as first failure died, of whom 19 died from 
the metastases. Salvage treatment of vaginal relapse was often successful. After vaginal 
recurrence, the two-year survival rate was 79% in contrast to 21% after pelvic or distant 
relapse. At three years, the survival was 69% and 13%, respectively (p=0.001). As for the 
survival after first relapse by treatment arm, the survival rate was better for patients in the 
control group than for patients in the radiotherapy group (p=0.02). The authors concluded 
that post-operative radiotherapy in Stage 1 endometrial carcinoma reduces locoregional 
recurrence but has no impact on overall survival and that radiotherapy increases treatment-
related morbidity. Therefore, a trade-off between the risk of locoregional recurrence and the 
survival rate after salvage treatment on the one hand, and the morbidity and cost of 
adjuvant pelvic radiotherapy on the other, has to be made for each subgroup of Stage 1 
endometrial carcinoma. These findings further support the need for a systematic LND 
whenever possible for patients with intermediate or high risk of endometrial cancer.  
8.2 Conclusion 
Adjuvant radiotherapy cannot be substituted for a systematic LND in intermediate- and 
high-risk endometrial cancer patients.  
9. Areas for future research 
9.1 Sentinel Lymph Node (SLN) 
From the evidence presented above, it is clear that for patients with endometrial cancer who 
are at risk of lymph node metastasis, the site of metastasis can be in the pelvic LNs or the 
para-aortic LN chain up to the renal vessels. Removal of metastatic lymph nodes has 
prognostic and therapeutic value. On the other hand, the addition of a systematic PLND and 
PaLND to a standard hysterectomy and bilateral salpingo-oophorectomy, increases the 
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technical difficulty of the surgery, requires more operating time and increases the risk of 
intra-operative and postoperative complications. These problems apply even when a 
minimally invasive surgical approach is adopted. Therefore, the challenge is to identify a 
surgical technique that provides accurate staging information about nodal status, while 
avoiding unnecessary morbidity. 
Sentinel lymph node detection might resolve this dilemma. This technique is based upon the 
observation that in several types of cancer, tumor cells migrate from the primary tumor to 
one or a few lymph nodes before metastasizing to other lymph nodes (melanoma, breast, 
cervix, vulva) (Altgassen et al., 2008; Hauspy et al., 2007a&b). Lymphatic mapping by 
sentinel lymph node (SLN) detection offers a means of assessing the lymph node status of 
primary tumors with respect to metastases, without having to resort to formal LND.  
In a meta-analysis of various techniques to assess lymph node status in endometrial cancer, 
Selmanet al. (2008) showed that SLN biopsy was more accurate than MRI and CT scan. In 
endometrial cancer, several approaches have been attempted: serosal injection during 
surgery, cervical injection or peri-tumoral injection using hysteroscopic assistance. With 
cervical injection, detection rates of sentinel lymph nodes in low-risk endometrial cancer 
reach 85% (Abu-Rustum et al., 2009). A recent study in early invasive cancer suggested that 
SLN biopsy is a more sensitive procedure to detect pelvic lymph node metastasis compared 
to the classic PLND due to more extensive sectioning by the pathologist of this LN, its 
occasionally unusual location (common iliac or para-aortic) and the surgeon’s thorough 
search for this blue or ”hot” node (Gortzak-Uzan et al., 2010). Similarly, in early-stage 
endometrial cancer, SLN mapping appears to be a more sensitive procedure for detecting 
PLN metastasis compared to the classic PLND for the same reasons: the surgeon’s thorough 
search for this sentinel node and extensive sectioning by the pathologist of the sentinel 
lymph node (Khoury-Collado et al., 2011).  
A French multicentre study (SENTI-ENDO) prospectively evaluated the ability of cervical 
dual injection of technetium and patent blue to identify SLN in patients with endometrial 
cancer (Ballester et al 2011). One hundred thirty-three patients were enrolled at nine centers 
in France. At least one SLN was detected in 111 of the 125 eligible patients; 17% had pelvic 
lymph node metastases and 5% had an associated SLN in the para-aortic area. Three 
patients had false-negative results (two had metastatic nodes in the contralateral pelvic area 
and one in the para-aortic area), giving an NPV of 97% (95% CI 91 to 99) and sensitivity of 
84% (62 to 95). All three of the patients in whom the SLN was negative in the presence of 
metastatic nodes had Type 2 endometrial cancer. Ultrastaging detected metastases, which 
were missed by conventional histology in nine of 111 (8%) patients with detected SLNs, 
representing nine of the 19 patients (47%) with metastases. SLN biopsy upstaged 10% of 
patients with low-risk and 15% of those with intermediate-risk endometrial cancer.  
This study highlights the danger of omitting lymphadenectomy in patients with early-stage 
endometrial cancer, as suggested by the ASTEC study, as 11% of patients at low risk for 
lymph node metastasis (Grade 1, endometrioid cancer with no myometrial invasion), had 
positive lymph node metastasis. The authors conclude that SLN biopsy with cervical dual 
labeling could be a trade-off between systematic LND and no dissection at all in patients 
with low or intermediate risk endometrial cancer.  
The limitations with this study are that the investigators used only cervical injection for the 
SLN mapping, which is not ideal to identify PaLNs. In a review of SLNs in endometrial 
cancer, Delpech et al 2008, reported a lower rate of para-aortic SLN detection using cervical 
www.intechopen.com
 
Controversies Regarding the Utility of Lymphadenectomy in Endometrial Cancer 
 
113 
injection alone compared with cervical and  subserosal or subendometrial injection of patent 
blue. Additionally, in the SENTI-ENDO study, PaLND was not done if the PLND did not 
identify metastasis. This means that the incidence of para-aortic metastases could have been 
underestimated, as about 10% to 16% of lymph node metastases occur exclusively in the 
para-aortic region.  
An experimental study on female cadavers by Lecuru et al 1997, had identified that one of 
the main routes of lymphatic drainage from the uterus ran along the infundibulo-pelvic 
ligament to the para-aortic area. Furthermore, when sentinel lymph node were identified 
using hysteroscopic injection to the tumor base, the para-aortic region was shown to be an 
important site of sentinel nodes in endometrial cancer, with 14% of SLN being exclusively in 
the para-aortic region and 47% of para-aortic sentinel nodes located above the inferior 
mesenteric artery (Nijkura et al., 2004). This method is technically more demanding. 
Nevertheless, if sentinel lymph node mapping is to replace surgical staging for endometrial 
cancer, we are obliged to investigate and adopt the most accurate rather than the most 
expedient method of identifying the sentinel lymph node. 
10. Conclusion 
Patients who have Grade I/II, endometrioid adenocarinoma with minimal myometrial 
invasion have very low risk of lymph node metastasis and do not benefit from LND. 
However, only a thoroughly detailed intra-operative frozen section can identify this 
subgroup. All high-risk patients need a systematic PLND as well as a PaLND up to the renal 
vessels. Such dissection needs considerable technical skills on the part of surgeons, and has 
risk for patients; but confers a significant survival advantage. Analysis of numerous nodes, 
particularly when they are small, is tedious for the pathologist. Therefore, SLN mapping has 
the potential to identify the subset of low-/intermediate-risk patients who do not need 
lymph node dissection. Research needs to be directed at finding the most accurate method 
of identifying the sentinel lymph node/nodes in endometrial cancer. This will allow the 
judicious use of resources, including time, cost and energy, to recover the appropriate 
number of lymph nodes in high-risk patients who will benefit from this procedure. 
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